Wealth Enhancement Advisory Services
RXRX icon

Wealth Enhancement Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Buy
47,120
+12,842
+37% +$42.8K ﹤0.01% 3655
2026
Q1 		$107K Buy
34,278
+14,068
+70% +$54.4K ﹤0.01% 3306
2025
Q4 		$92K Buy
20,210
+1,114
+6% +$5.52K ﹤0.01% 3449
2025
Q3 		$99.9K Buy
19,096
+8,186
+75% +$43K ﹤0.01% 3336
2025
Q2 		$57.5K Sell
10,910
-13,320
-55% -$65.4K ﹤0.01% 3211
2025
Q1 		$128K Buy
24,230
+5,278
+28% +$38.5K ﹤0.01% 2715
2024
Q4 		$128K Buy
+18,952
New +$127K ﹤0.01% 2769

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wealth Enhancement Advisory Services's RXRX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Recursion Pharmaceuticals (RXRX) stake by 37% in Q2 2026, buying an estimated $42.8K and bringing the position to 47,120 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

Wealth Enhancement Advisory Services first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 47,120 shares of Recursion Pharmaceuticals worth $168K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 12,842 Recursion Pharmaceuticals shares in Q2 2026, an estimated $42.8K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3655 holding.
  • Wealth Enhancement Advisory Services first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.